High serum HTATIP2/TIP30 level in serous ovarian cancer as prognostic or diagnostic marker

European Journal of Medical Research

Volumn 18, Issue 1, 2013, Pages

  Kumtepe, Yakup ^a   Halici, Zekai ^a   Sengul, Ozlem ^b   Kunak, Celalettin Semih ^c   Bayir, Yasin ^d   Kilic, Nergiz ^e   Cadirci, Elif ^d   Pulur, Alparslan ^a   Bayraktutan, Zafer ^f  

^a ATATURK UNIVERSITY   (Turkey)

^b Yenimahalle Government Hospital   (Turkey)

^c GIRESUN UNIVERSITY   (Turkey)

^d ATATÜRK UNIVERSITY   (Turkey)

^e KAFKAS UNIVERSITY   (Turkey)

^f Erzurum Region Education and Research Hospital   (Turkey)

Author keywords

adenocarcinoma; HTATIP2 TIP30; ovarian cancer

Indexed keywords

HIV 1 TAT INTERACTIVE PROTEIN 2; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; ACYLTRANSFERASE; HTATIP2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; OVARY CANCER; PROTEIN BLOOD LEVEL; ADENOCARCINOMA; BLOOD; DIFFERENTIAL DIAGNOSIS; GYNECOLOGIC DISEASE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; OVARY TUMOR; PATHOGENICITY; PATHOLOGY; PROGNOSIS; VIROLOGY;

ACETYLTRANSFERASES; ADENOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENITAL DISEASES, FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 84879219116     PISSN: 09492321     EISSN: 2047783X     Source Type: Journal    
DOI: 10.1186/2047-783X-18-18     Document Type: Article

References (30)

1. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L, Mills GB, J Oncol 2010 2010 568938 20037743
2. Precursor lesions of ovarian epithelial malignancy. Feeley KM, Wells M, Histopathology 2001 38 87 95 10.1046/j.1365-2559.2001.01042.x 11207821
3. Epidermal growth factor receptor blockers for the treatment of ovarian cancer. Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S, Morrison J, Cochrane Database Syst Rev 2011 5 CD007927
4. Revised FIGO staging for gynecological cancer. Shepherd JH, Br J Obstet Gynecol 1989 96 889 892 10.1111/j.1471-0528.1989.tb03341.x
5. Mechanism of action of trastuzumab and scientific update. Baselga J, Albanell J, Molina MA, Arribas J, Semin Oncol 2001 28 4 11 11706390
6. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Cooley S, Burns LJ, Repka T, Miller JS, Exp Hematol 1999 27 1533 1541 10.1016/S0301-472X(99)00089-2 10517495
7. Drug discovery in ovarian cancer. Chase DM, Mathur N, Tewari KS, Recent Pat Anticancer Drug Discov 2010 5 251 260 10.2174/157489210791760472 20524931
8. Contribution of immunohistochemistry in prognostic assessment of epithelial ovarian carcinoma-review of the literature I. Tomsova M, Melichar B, Acta Medica (Hradec Kralove) 2006 49 161 165
9. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR, J Clin Oncol 2003 21 283 290 10.1200/JCO.2003.10.104 12525520
10. Overexpression of CC3/TIP30 is associated with HER2/neu status in breast cancer. Zhang DH, Wong LL, Tai LK, Koay ES, Hewitt RE, J Cancer Res Clin Oncol 2005 131 603 608 10.1007/s00432-005-0674-z 15931508
11. A cofactor, TIP30, specifically enhances HIV-1 Tat-activated transcription. Xiao H, Tao Y, Greenblatt J, Roeder RG, Proc Natl Acad Sci USA 1998 95 2146 2151 10.1073/pnas.95.5.2146 9482853
12. TIP30 has an intrinsic kinase activity required for up-regulation of a subset of apoptotic genes. Xiao H, Palhan V, Yang Y, Roeder RG, EMBO J 2000 19 956 963 10.1093/emboj/19.5.956 10698937
13. TIP30 deficiency increases susceptibility to tumorigenesis. Ito M, Jiang C, Krumm K, Zhang X, Pecha J, Zhao J, Guo Y, Roeder RG, Xiao H, Cancer Res 2003 63 8763 8767 14695192
14. Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro. NicAmhlaoibh R, Shtivelman E, Oncogene 2001 20 270 275 10.1038/sj.onc.1204075 11313954
15. TIP30 regulates apoptosis-related genes in its apoptotic signal transduction pathway. Shi M, Zhang X, Wang P, Zhang HW, Zhang BH, Wu MC, World J Gastroenterol 2005 11 221 227 15633220
16. A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma. Shtivelman E, Oncogene 1997 14 2167 2173 10.1038/sj.onc.1201059 9174052
17. TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU. Zhao J, Zhang X, Shi M, Xu H, Jin J, Ni H, Yang S, Dai J, Wu M, Guo Y, Hepatology 2006 44 205 215 10.1002/hep.21213 16799960
18. TIP30 interacts with an estrogen receptor alpha-interacting coactivator CIA and regulates c-Myc transcription. Jiang C, Ito M, Piening V, Bruck K, Roeder RG, Xiao H, J Biol Chem 2004 279 27781 27789 10.1074/jbc.M401809200 15073177
19. Cloning, expression, purification, and characterization of AmphiTip30, a member of short-chain dehydrogenases/reductases family from the amphioxus Branchiostoma belcheri tsingtauense. Wang S, Zhao B, Zhang S, Ji H, Protein Expr Purif 2008 57 63 71 10.1016/j.pep.2007.08.014 17950618
20. Decreased TIP30 expression promotes tumor metastasis in lung cancer. Tong X, Li K, Luo Z, Lu B, Liu X, Wang T, Pang M, Liang B, Tan M, Wu M, Zhao J, Guo Y, Am J Pathol 2009 174 1931 1939 10.2353/ajpath.2009.080846 19349353
21. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Jiao Y, Ou W, Meng F, Zhou H, Wang A, Mol Cancer 2011 10 125 10.1186/1476-4598-10-125 21962244
22. Alternatively spliced products CC3 and TC3 have opposing effects on apoptosis. Whitman S, Wang X, Shalaby R, Shtivelman E, Mol Cell Biol 2000 20 583 593 10.1128/MCB.20.2.583-593.2000 10611237
23. Mechanisms of estrogen action. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA, Physiol Rev 2001 81 1535 1565 11581496
24. AIB1 enhances estrogen-dependent induction of cyclin D1 expression. Planas-Silva MD, Shang Y, Donaher JL, Brown M, Weinberg RA, Cancer Res 2001 61 3858 3862 11358796
25. The human c-Myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. Battey J, Moulding C, Taub R, Murphy W, Stewart T, Potter H, Lenoir G, Leder P, Cell 1983 34 779 787 10.1016/0092-8674(83)90534-2 6414718
26. Mechanism of estrogen activation of c-Myc oncogene expression. Dubik D, Shiu RP, Oncogene 1992 7 1587 1594 1630819
27. Consequences of widespread deregulation of the c-Myc gene in transgenic mice: multiple neoplasms and normal development. Leder A, Pattengale PK, Kuo A, Stewart TA, Leder P, Cell 1986 45 485 495 10.1016/0092-8674(86)90280-1 3011271
28. c-Myc in breast cancer. Liao DJ, Dickson RB, Endocr Relat Cancer 2000 7 143 164 10.1677/erc.0.0070143 11021963
29. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE, Oncogene 2000 19 968 988 10.1038/sj.onc.1203277 10713680
30. Paracrine mechanisms of mouse mammary ductal growth. Cunha GR, Wiesen JF, Werb Z, Young P, Hom YK, Cooke PS, Lubahn DB, Adv Exp Med Biol 2000 480 93 97 10959414